Sarepta to buy Myonexus to expand muscular dystrophy therapy portfolio
Category: #health  By Mateen Dalal  Date: 2019-02-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sarepta to buy Myonexus to expand muscular dystrophy therapy portfolio

Sarepta Therapeutics has recently confirmed that it is planning to acquire Myonexus Therapeutics in a $165 million deal, by exercising a purchase option that was part of a gene therapy partnership commenced by the firms in the previous year.

The transaction is aimed at broadening the pipeline of Sarepta with the five Myonexus candidates. Supposedly, these five candidates all use the same gene therapy platform that was licensed from Nationwide Children’s Hospital, designed for delivering treatment to skeletal and cardiac muscle robustly and systematically, without crossing the blood-brain barrier promiscuously.

According to Sarepta, all the five gene therapy candidates have been developed for offering the first-ever corrective therapy for five distinctive Limb-girdle muscular dystrophy (LGMD) forms, which are LGMD2B, LGMD2C, LGMD2D, LGMD2E, and LGMD2L.

The firm informed that three of the five programs are presently in clinical stages. MYO-101 from Myonexus, designed for LGMD2E, is the furthest in development and is aimed at restoring the dystrophin-related protein complex by transferring a gene which codes for and restores beta-sarcoglycan protein.

Myonexus, in November 2018, had unveiled the launch of a first-in-human, Phase I/IIa trial for MYO-101. It was a placebo-controlled study designed for evaluating a single infusion of MYO-101 intravenously among children aged between 4 and 15 years and having LGMD2E, with considerable symptoms of the disease.  

Apparently, the study was designed to assess up to two levels of dosage of the gene therapy candidate in two cohorts among nine patients, with their baseline measurements established on the basis of a recruitment study.

Doug Ingram, president and CEO of Sarepta, said acquiring Myonexus will enable the company to rapidly move and find solutions for LGMD patients, while continuing to develop and validate its gene therapy engine. The five gene therapies for LGMD under development are an ideal fit for the mission of Sarepta, to develop therapies having the potential to rescue patient lives from serious and life-limiting rare genetic disorders, Ingram added.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
By Mateen Dalal

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristo...

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
By Mateen Dalal

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acqu...

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...